DCM
AVIR icon

Discovery Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Discovery Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-596,800
Closed -$5.33M – 76
2021
Q4 		$5.33M Buy
596,800
+434,000
+267% +$6.76M 0.4% 45
2021
Q3 		$5.71M Buy
+162,800
New +$4.52M 0.43% 40

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Discovery Capital Management's AVIR Position: Q1 2022 in Review

Discovery Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 596,800 shares — an estimated $5.33M sold.

Discovery Capital Management first reported a position in AVIR in Q3 2021 and held it in 2 quarters. The position peaked at $5.71M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Discovery Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Discovery Capital Management sold 596,800 Atea Pharmaceuticals shares in Q1 2022, an estimated $5.33M.
  • Discovery Capital Management first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Discovery Capital Management's Atea Pharmaceuticals position peaked at $5.71M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Discovery Capital Management's 13F filing for Q1 2022, filed 16 May 2022.